Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Viridian Therapeutics, Inc., VRDN
Summary: Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
- Last Price: $17.55
- Price Change: $-0.46, -2.55%
- Yearly Gain: -31.53%
- Market Cap: $1.10B
- P/E Ratio: -3.31
Here are 3rd party ratings for VRDN:
- TipRanks.com: Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 33% (83 out of 252)
What is the sentiment on the street regarding Viridian Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in VRDN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on VRDN before you decide to make any investment.
Click here for chart >>
OmniAb, Inc., OABI
Summary: OmniAb Inc. discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. OmniAb Inc., formerly known as Avista Public Acquisition Corp. II, is based in SAN DIEGO.
- Last Price: $5.31
- Price Change: $0.18, 3.51%
- Yearly Gain: 57.57%
- Market Cap: $620.52M
- P/E Ratio: -20.42
Here are 3rd party ratings for OABI:
- TipRanks.com: Buy
- TradingView.com: sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 39% (99 out of 252)
What is the sentiment on the street regarding OmniAb, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus: {Blogger Consensus}
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in OABI or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on OABI before you decide to make any investment.
Click here for chart >>
Castle Biosciences, Inc., CSTL
Summary: Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.
- Last Price: $20.82
- Price Change: $0.55, 2.71%
- Yearly Gain: -8.00%
- Market Cap: $571.51M
- P/E Ratio: -9.73
Here are 3rd party ratings for CSTL:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 33% (83 out of 252)
What is the sentiment on the street regarding Castle Biosciences, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CSTL or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CSTL before you decide to make any investment.
Click here for chart >>
Verastem, Inc., VSTM
Summary: Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
- Last Price: $11.53
- Price Change: $-0.51, -4.24%
- Yearly Gain: 128.77%
- Market Cap: $291.66M
- P/E Ratio: -2.91
Here are 3rd party ratings for VSTM:
- TipRanks.com: Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Verastem, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in VSTM or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on VSTM before you decide to make any investment.
Click here for chart >>
Thanks for reading!